Neurofibromatosis 2011: A report of the Children's Tumor Foundation Annual Meeting

Acta Neuropathologica

Volumn 123, Issue 3, 2012, Pages 369-380

  Kalamarides, Michel ^a,u   Acosta, Maria T ^b   Babovic Vuksanovic, Dusica ^c   Carpen, Olli ^d   Cichowski, Karen ^e   Gareth Evans, D ^f   Giancotti, Filippo ^g   Oliver Hanemann, C ^h   Ingram, David ⁱ   Lloyd, Alison C ^j   Mayes, Debra A ^k   Messiaen, Ludwine ^l   Morrison, Helen ^m   North, Kathryn ⁿ   Packer, Roger ^b   Pan, Duojia ^o   Stemmer Rachamimov, Anat ^p   Upadhyaya, Meena ^q   Viskochil, David ^r   Wallace, Margret R ^s   Hunter Schaedle, Kim ^t   Ratner, Nancy ^k   more..

^a INSERM   (France)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TURKU   (Finland)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF PLYMOUTH   (United Kingdom)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m FRITZ LIPMANN INSTITUTE   (Germany)

ⁿ CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p MASSACHUSETTS GENERAL HOSPITAL   (United States)

^q CARDIFF UNIVERSITY   (United Kingdom)

^r UNIVERSITY OF UTAH   (United States)

^s UNIVERSITY OF FLORIDA   (United States)

^t Children's Tumor Foundation   (United States)

^u BEAUJON HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; COLECALCIFEROL; CYCLIC AMP; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IMMUNOMODULATING AGENT; METHYLPHENIDATE; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONCOPROTEIN; PROSTAGLANDIN D SYNTHASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; RAS PROTEIN; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; V RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ATTENTION DEFICIT DISORDER; AUTOPHAGY; BONE DENSITY; BRAIN SIZE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CAUSE OF DEATH; CELL PROLIFERATION; CHILDREN TUMOR FOUNDATION ANNUAL MEETING; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; COGNITIVE DEFECT; CONFERENCE PAPER; COPY NUMBER VARIATION; DISEASE CLASSIFICATION; DNA SEQUENCE; DRUG EFFICACY; EPENDYMOMA; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; IDH1 GENE; IDH2 GENE; LEARNING DISORDER; MENDELIAN DISEASE; MENINGIOMA; NEURAL STEM CELL; NEURILEMOMA; NEURINOMA; NEUROFIBROMA; NEUROFIBROMATOSIS; NONHUMAN; OLIGODENDROGLIA; ONCOGENE; OPTIC NERVE GLIOMA; PDGFR GENE; PERIPHERAL NERVOUS SYSTEM; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RARE DISEASE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR REGRESSION; UNITED STATES; WORLD HEALTH ORGANIZATION;

CHILD; GENES, NEUROFIBROMATOSIS 1; GENES, NEUROFIBROMATOSIS 2; HUMANS; MENINGIOMA; NEURILEMMOMA; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2;

EID: 84857917804     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-011-0905-0     Document Type: Conference Paper

References (25)

1. Acosta MT, Kardel PG, Walsh KS, Rosenbaum K, Gioia GA, Packer RJ (2011) Lovastatin improves cognitive deficits in NF1: safety and efficacy study. Ped Neurol 45(4):241-245
2. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG (2008) Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 67(9):878-887
3. Brown JA, Emnett RJ, White CR et al (2010) Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis- 1 mutant mice. Hum Mol Genet 19:4515-4528
4. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
5. Denayer E, Ahmed T, Brems H et al (2008) Spred1 is required for synaptic plasticity and hippocampus-dependent learning. J Neurosci 28:14443-14449
6. De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K (2011) Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20(3):400-413
7. Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M (2011) Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 22:990-991
8. Halder G, Johnson RL (2011) Hippo signaling: growth control and beyond. Development 138:9-22
9. Hyman SL, Gill DS, Shores EA, Steinberg A, North KN (2007) T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry 78(10):1088-1091
10. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M et al (2011) Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 30:2333-2344
11. Lauchle JO, Kim D, Le DT et al (2009) Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 461:411-414
12. Li W, You L, Cooper J et al (2010) Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4 (DCAF1) in the nucleus. Cell 140:477-490
13. Liu C, Sage JC, Miller MR et al (2011) Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146:209-221
14. Lopez G, Torres K, Lev D (2011) Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: potential implications for the treatment of a therapeutic-resistant malignancy. Autophagy 7(4):440-441 (Epub 2011 Apr 1)
15. Lorenzo J, Barton B, Acosta MT, North KN (2011) The mental motor and language development of toddlers with neurofibromatosis type 1. J Pediatr 158:660-665
16. Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG (2011) Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol 70:568-577
17. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358-367
18. Pride N, Payne JM, Webster R, Shores EA, Rae C, North KN (2010) Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol 25:834-841
19. Raabe EH, Lim KS, Kim JM et al (2011) BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res 17:3590-3599
20. Slattery WH, Hoa M, Bonne N et al (2011) Middle fossa decompression for hearing preservation: a review of institutional results and indications. Otol Neurotol 32:1017-1024
21. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
22. Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, Schnell BM, Kim MO, Kim A, Widemann BC, Cripe TP, Ratner N (2011) Preclincial testing of Sorafenib and RAD001 in the Nf(flox/flox);DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer. doi: 10.1002/pbc.23015
23. Yang et al (2008) Nf1-dependent tumors require a microenvironment containing Nf1± and c-kit-dependent bone marrow. Cell 135(3):437-448
24. Yi C, Troutman S, Fera D et al (2011) A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 19:527-540
25. Zhang N, Bai H, David KK et al (2010) The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19:27-38